The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

In the final episode, ‘The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma,’ the panelists explored the following critical questions:

Do you envision combination therapy having a bigger role in the future in patients with extrapulmonary neuroendocrine carcinoma?

Do you foresee therapeutic options getting more personalized in the future in patients with extrapulmonary neuroendocrine carcinoma?

Which additional data are you looking to see with the therapies under investigation for extrapulmonary neuroendocrine carcinoma?

What are your final takeaways on the management of extrapulmonary neuroendocrine carcinoma?

Led by the moderator, the panelists examined the future of combination therapy in extrapulmonary neuroendocrine carcinoma (epNEC), drawing on lessons from prostate cancer and non-small cell lung cancer to illustrate how combining chemotherapy with novel targeted agents or immunotherapy can produce deeper and more durable responses than chemotherapy alone. William Oh, Namrata Vijayvergia, Sandy Kotiah, and Aman Chauhan discussed the growing expectation that treatment will become increasingly personalized as the field develops a deeper understanding of tumor biology, organ-specific microenvironments, and the differential expression of targets such as delta-like ligand 3 (DLL3) across primary sites. The panelists highlighted the additional data still needed — including toxicity profiles of emerging agents, comparative efficacy across epNEC subtypes, and biomarker-driven patient selection — to refine treatment algorithms and better match therapies to individual patients. In their final takeaways, the panelists emphasized the importance of adopting the epNEC terminology to facilitate drug development, standardizing pathology reporting, ensuring timely and accurate diagnosis, and referring patients to clinical trials early, as breakthrough advances in this space will depend on robust trial participation and continued collaboration across the oncology community.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Peer Exchange series on extrapulmonary neuroendocrine carcinoma (epNEC). Please subscribe to our newsletter for information on upcoming video series.